Press Release: January 19, 2017
“Although the overall POC market is expected to grow steadily, infectious POC is expected to witness highest CAGR “, says RNCOS.
Infectious Disease Testing is amongst one of the top disease classes impacted currently by POC testing. Innovative point-of-care molecular diagnostic platforms enable rapid and accurate identification of infectious disease pathogens, even in low resource settings and remote areas. Global epidemiological outbreak by the Ebola, MERS, Zika, Dengue and Chikungunya viruses demand for simple rapid molecular tests that can help determine optimal treatment, curb the spread of infections, and assist with allocation of resources.
POC infectious disease testing products can be used to screen and diagnose a wide range of illnesses, including respiratory diseases such as Tuberculosis, HIV, hepatitis, influenza, common illnesses such as Strep A and H. pylori that cause stomach ulcers, sexually-transmitted infections (STIs) and tropical diseases such as malaria and Dengue fever. This market is likely to be driven by increasing prevalence of infectious diseases. For instance, Chlamydia and syphilis have the highest incidence rates in the US, among positively trending infectious diseases, combined with gonorrhoea, HPV, HCV, and HIV, STDs exhibiting huge market opportunity in the US.
According to “Global Point of Care Testing Market, by Product (Glucometers, BGE Analyzers, Pregnancy Tests, Infectious Diseases, etc.), Outlook 2022” report, owing to all these factors, the market for Infectious diseases testing kits is anticipated growing at a high CAGR over the forecasted period. In addition, availability of rapid random access molecular diagnostic system for critical care infectious diseases such as MRSA and sepsis in the near future is likely to be a significant driver of infectious POCT market.
There are several companies active in the POC infectious disease testing market. Alere, Chembio Diagnostics, OraSure Technologies and Trinity Biotech hold strong market positions for HIV testing. Similarly, Alere and Quidel are leading the market for respiratory disease diagnostics and for other POC tests commonly used in physician's offices. The major companies operating in the global point of care infectious disease diagnostics market are Thermo Fisher Scientific Inc., Alere Inc., Chembio Diagnostic Systems, Inc., Meridian Bioscience, Inc., Trinity Biotech plc, Sekisui Diagnostics, OraSure Technologies, Inc., and Quidel Corporation.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM878.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
For more information, please contact:
Visit the newsroom of: email@example.com